Develops drugs for thyroid eye disease and autoimmune disorders.
Jun 2026Revenue $71.1M/yrExpenses $476M/yr
No trend
Figures by year
When will Viridian Therapeutics, Inc.\DE be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $71.1M and expenses $476M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $70.8M | $434M | −$363M |
| Dec 2024 | $302K | $299M | −$299M |
| Dec 2023 | $314K | $255M | −$254M |
| Dec 2022 | $1.77M | $136M | −$134M |
| Dec 2021 | $2.96M | $82.7M | −$79.7M |
| Dec 2020 | $1.05M | $111M | −$110M |
| Dec 2019 | $4.46M | $46.4M | −$42.0M |
| Dec 2018 | $8.39M | $41.5M | −$33.1M |
| Dec 2017 | $4.00M | $30.5M | −$26.5M |
| Dec 2016 | $3.48M | $20.5M | −$17.0M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.